Peter M Andersen
Overview
Explore the profile of Peter M Andersen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
228
Citations
9800
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Axakova A, Ding M, Cote A, Subramaniam R, Senguttuvan V, Zhang H, et al.
bioRxiv
. 2025 Mar;
PMID: 40060668
Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease for which important subtypes are caused by variation in the Superoxide Dismutase 1 gene . Diagnosis based on sequencing can...
2.
Iacoangeli A, Dilliott A, Al Khleifat A, Andersen P, Basak N, Cooper-Knock J, et al.
J Neurol Neurosurg Psychiatry
. 2025 Feb;
PMID: 39947885
Background: Despite several studies suggesting a potential oligogenic risk model in amyotrophic lateral sclerosis (ALS), case-control statistical evidence implicating oligogenicity with disease risk or clinical outcomes is limited. Considering its...
3.
4.
Dash B, Freischmidt A, Helferich A, Ludolph A, Andersen P, Weishaupt J, et al.
Front Cell Neurosci
. 2024 Nov;
18:1457704.
PMID: 39588282
Amyotrophic lateral sclerosis (ALS) is a fatal, adult-onset disease marked by a progressive degeneration of motor neurons (MNs) present in the spinal cord, brain stem and motor cortex. Death in...
5.
Leykam L, Forsberg K, Nordstrom U, Hjertkvist K, Oberg A, Jonsson E, et al.
Neurobiol Dis
. 2024 Nov;
202:106718.
PMID: 39490682
Mutations in superoxide dismutase-1 (SOD1) are a cause of hereditary amyotrophic lateral sclerosis (ALS) through a gain-of-function mechanism involving unfolded mutant SOD1. Intrathecal gene therapy using the antisense-oligo-nucleotide drug tofersen...
6.
Roos A, Stenvall E, Kockum E, Gronlund K, Alstermark H, Wuolikainen A, et al.
Hum Mol Genet
. 2024 Sep;
33(22):1966-1974.
PMID: 39270726
Short tandem repeat expansions in the human genome are overrepresented in a variety of neurological disorders. It was recently shown that huntingtin (HTT) repeat expansions with full penetrance, i.e. 40...
7.
Winroth I, Borjesson A, Andersen P, Karlsson T
J Clin Exp Neuropsychol
. 2024 Sep;
46(7):669-682.
PMID: 39258714
Objective: Cognitive decline is common in patients with amyotrophic lateral sclerosis (ALS), especially in carriers of the mutation . However, cognitive impairment is poorly understood in carriers of mutations in...
8.
Weishaupt J, Kortvelyessy P, Schumann P, Valkadinov I, Weyen U, Hesebeck-Brinckmann J, et al.
Commun Med (Lond)
. 2024 Jul;
4(1):150.
PMID: 39054363
Background: Since the antisense oligonucleotide tofersen has recently become available for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in SOD1, determining the causality of the over 230...
9.
Malmstrom N, Ohlen J, Jakobsson Larsson B, Nilsson S, Nygren I, Andersen P, et al.
Soc Sci Med
. 2024 Jul;
354:117063.
PMID: 38971043
Objective: The study aimed to explore the meaning for adolescents of living with a parent with amyotrophic lateral sclerosis (ALS). Methods: The design is qualitative. Interviews were conducted between December...
10.
Benatar M, Wuu J, Huey E, McMillan C, Petersen R, Postuma R, et al.
Nat Rev Neurol
. 2024 May;
20(6):377.
PMID: 38811858
No abstract available.